高三尖杉酯碱对白血病细胞凋亡、增殖的影响及对Ras/Raf/MEK通路的抑制作用

doi:10.20047/j.issn1673-7210.2023.25.03

摘要
图/表
参考文献(26)
相关文章 (15)

全文: PDF (1565 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨高三尖杉酯碱（HHT）对白血病细胞凋亡、增殖的影响及对Ras/Raf/MEK通路的抑制作用。方法取对数生长期K562、Kasum-1细胞进行研究，分别用0、10、20、50 ng/ml的HHT处理。采用MTT检测相对细胞活力，计算24、48、72 h时细胞IC50，采用克隆形成实验检测检测细胞克隆数量，采用流式细胞仪检测细胞凋亡水平，采用蛋白质印迹法检测Ras/Raf/MEK通路蛋白和凋亡相关蛋白相对水平。结果 24、48、72 h时HHT对K562细胞IC50分别为80.69、65.28、50.76 ng/ml，HHT对Kasum-1细胞IC50分别为85.16、70.11、51.14 ng/ml。培养24、48、72 h时，10、20、50 ng/ml HHT细胞存活率均低于0 ng/ml，20、50 ng/ml HHT细胞存活率均低于10 ng/ml，50 ng/ml HHT细胞存活率均低于20 ng/ml HHT，差异有统计学意义（P＜0.05)。10、20、50 ng/ml HHT细胞克隆数均低于0 ng/ml，20、50 ng/ml HHT细胞克隆数均低于10 ng/ml HHT，50 ng/ml HHT细胞克隆数均低于20 ng/ml HHT，差异有统计学意义（P＜0.05）。10、20、50 ng/ml HHT细胞凋亡率均高于0 ng/ml HHT，20、50 ng/ml HHT细胞凋亡率均高于10 ng/ml HHT，50 ng/ml HHT细胞凋亡率均高于20 ng/ml HHT，差异有统计学意义（P＜0.05）。10、20、50 ng/ml HHT RAS、p-cRAF、p-MEK蛋白表达量均低于0 ng/ml HHT，20、50 ng/ml HHT RAS、p-cRAF、p-MEK蛋白表达量均低于10 ng/ml HHT，50 ng/ml HHT RAS、p-cRAF、p-MEK蛋白表达量均低于20 ng/ml HHT，差异有统计学意义（P＜0.05）。10、20、50 ng/ml HHT Survivan蛋白表达量均低于0 ng/ml HHT，Cleaved caspase-3、Cleaved PARP蛋白表达量均高于0 ng/ml HHT；20、50 ng/ml HHT Survivan蛋白表达量均低于10 ng/ml HHT，Cleaved caspase-3、Cleaved PARP蛋白表达量均高于10 ng/ml HHT、50 ng/ml HHT Survivan蛋白表达量均低于20 ng/ml HHT，Cleaved caspase-3、Cleaved PARP蛋白表达量均高于20 ng/ml HHT，差异有统计学意义（P＜0.05）。结论 HHT可抑制Ras/Raf/MEK通路活性，抑制白血病细胞增殖和促进白血病细胞凋亡。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	齐海燕　　蓝建平　　宋晓露　　王晓刚　　王文松

关键词 ：高三尖杉酯碱, Ras/Raf/MEK通路, 白血病, 凋亡, 增殖

Abstract：Objective To investigate the effect of homoharringtonine (HHT) on apoptosis and proliferation of leukemia cells and its inhibitory effect on Ras/Raf/MEK pathway. Methods The logarithmic growth phase K562 and Kasum-1 cells were taken for study and treated with HHT of 0, 10, 20 , and 50 ng/ml, respectively. MTT was used to detect relative cell viability, clone formation assay was used to detect the number of cell clones, cell IC50 was calculated at 24, 48, and 72 hours, flow cytometry was used to detect the level of apoptosis, and Western blot was used to detect the relative levels of Ras/Raf/MEK pathway proteins and apoptosis-related proteins. Results At 24, 48, and 72 hours, the IC50 of HHT on K562 cells was 80.69, 65.28, and 50.76 ng/ml, respectively. The IC50 of HHT on Kasum-1 cells was 85.16, 70.11, and 51.14 ng/ml, respectively. When cultured for 24, 48, and 72 h, the survival rate of 10, 20 and 50 ng/ml HHT cells was lower than 0 ng/ml, and the survival rate of 20 and 50 ng/ml HHT cells was lower than 10 ng/ml. The survival rate of 50 ng/ml HHT cells was lower than that of 20 ng/ml HHT cells, and the differences were statistically significant (P＜0.05). The clones of 10, 20 and 50 ng/ml HHT cells were all lower than 0 ng/ml; the clones of 20 and 50 ng/ml HHT cells were all lower than 10 ng/ml HHT cells; the clones of 50 ng/ml HHT cells were all lower than 20 ng/ml HHT cells, and the differences were statistically significant (P＜0.05). The apoptosis rate of 10, 20, and 50 ng/ml HHT cells was higher than that of 0 ng/ml HHT cells, the apoptosis rate of 20 and 50 ng/ml HHT cells was higher than that of 10 ng/ml HHT cells, and the apoptosis rate of 50 ng/ml HHT cells was higher than that of 20 ng/ml HHT cells, and the differences were statistically significant (P＜0.05). The expression levels of RAS, p-cRAF, and p-MEK protein at 10, 20, and 50 ng/ml HHT were all lower than 0 ng/ml HHT, and the expression levels of RAS, p-cRAF, and p-MEK protein at 20 and 50 ng/ml HHT were all lower than 10 ng/ml HHT. The expression levels of RAS, p-cRAF, and P-MEK at 50 ng/ml HHT were lower than those of 20 ng/ml HHT, and the differences were statistically significant (P＜0.05). Survivan expression levels at 10, 20, and 50 ng/ml HHT were lower than 0 ng/ml HHT, Cleaved caspase-3 and Cleaved PARP were higher than 0 ng/ml HHT. Survivan expression at 20 and 50 ng/ml HHT was lower than that at 10 ng/ml HHT. Survivan expression levels were lower than 10, and 50 ng/ml HHT, respectively, Cleaved caspase-3 and Cleaved PARP expression levels were higher than 20 ng/ml HHT. The protein expression levels of Cleaved caspase-3 and Cleaved PARP were higher than 20 ng/ml HHT, and the differences were statistically significant (P＜0.05). Conclusion HHT can inhibit the activity of Ras/Raf/MEK pathway, inhibit the proliferation of leukemia cells, and promote apoptosis of leukemia cells.

Key words： Homoharringtonine Ras/Raf/MEK pathway Leukemia Apoptosis Proliferation

基金资助:浙江省医药卫生科技计划项目（2022KY045）。

通讯作者: 蓝建平（1969.4-），男，博士，主任医师；研究方向：血液系统恶性肿瘤、白血病造血干细胞移植等。

作者简介: 齐海燕（1982.6-），女，博士；研究方向：血液及肿瘤发病机制。

引用本文:

齐海燕　　蓝建平　　宋晓露　　王晓刚　　王文松. 高三尖杉酯碱对白血病细胞凋亡、增殖的影响及对Ras/Raf/MEK通路的抑制作用[J]. 中国医药导报, 2023, 20(25): 20-25,42.
QI Haiyan LAN Jianping SONG Xiaolu WANG Xiaogang WANG Wensong. Effect of homoharringtonine on lapoptosis and proliferation of leukemia cells and its inhibitory effect on Ras/Raf/MEK pathway. 中国医药导报, 2023, 20(25): 20-25,42.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.25.03 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I25/20

[1] Rocca A，Braga L，Volpe MC，et al. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer：Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets [J]. Cancers （Basel），2022，14（21）：5306.
[2] Jin H，Zhang Y，Yu S，et al. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML： A Multicenter，Phase 2 Trial [J]. J Hematol Oncol，2023，16（1）：42.
[3] Li J，Huang Y，Hou Y，et al. High efficacy of azacitidine combined with homoharringtonine，idarubicin，and cytarabine in newly diagnosed patients with AML：A single arm，phase 2 trial [J]. Front Oncol，2022，12：1069246.
[4] Plett R，Mellor P，Kendall S，et al. Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel [J]. Sci Rep，2022，12（1）：15663.
[5] PorcùE，Maule F，Manfreda L，et al. Identification of Homoharringtonine as a potent inhibitor of glioblastoma cell proliferation and migration [J]. Transl Res，2023，251：41-53.
[6] Zhang G，Song Y，Wan L，et al. Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine，cytarabine：A case report and literature review [J]. Blood Sci，2022，4（2）：93-96.
[7] Watari A，Fujiwara K，Yagi K，et al. Homoharringtonine is a transdermal granular permeation enhancer [J]. Biochem Biophys Res Commun，2022，616：140-144.
[8] 李芬芬，季斌.吉西他滨联合放射对人胰腺癌CFPAC-1细胞株裸鼠移植瘤EphB4、Caspase3表达的影响[J].实用癌症杂志，2022，37（10）：1570-1574，1595.
[9] Choi EY，Jung GH，Woo JS，et al. Dendropanax morbiferus H. Lus Leaf Extract Inhibits the Proliferation of MDA-MB-231 Breast Cancer Cells and Induces Apoptosis via the MAPK Pathway In Vitro and In Vivo [J]. Anticancer Res，2023，43（7）：3047-3056.
[10] Kim T，Kang JK，Hyun CG. 6-Methylcoumarin Promotes Me- lanogenesis through the PKA/CREB，MAPK，AKT/PI3K，and GSK3 6-Methylcoumarin Promotes Mel [J]. Molecules，2023，28（11）：4551.
[11] Wan W，Xiao W，Pan W，et al. Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk [J]. Cancer Chemother Pharmacol，2022，89（3）：401-411.
[12] Yang X，Shang P，Yu B，et al. Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ ERK signaling pathway [J]. Acta Pharm Sin B，2021，11（9）：2819-2834.
[13] Cortes J，Lipton JH，Rea D，et al. Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After Tki Failure in Patients With Chronic-Phase Cml With T315i Mutation [J]. Blood，2012，120（13）：2573-2580.
[14] Jin J，Wang JX，Chen FF，et al. Homoharringtonine-Based Induction Regimens for Patients With De-Novo Acute Mye- loid Leukaemia：A Multicentre，Open-Label，Randomised，Controlled Phase 3 Trial [J]. Lancet Oncol，2013，14（7）：599-608.
[15] Karmokar PF，Moniri NH. Free-fatty acid receptor-1 （FFA1/ GPR40） promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR，ERK1/2，STAT3 and EMT [J]. Cancer Cell Int，2023，23（1）：126.
[16] Mehdiüremi?鬤 M，üremi?鬤 N，Türk?觟zy Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/ Stat3，ERK/MAPK，PI3K/Akt/mTOR signaling pathways [J]. Ster- oids，2023，22：109261.
[17] Ware KE，Thomas BC，Olawuni PD，et al. A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in pros- tate cancer [J]. Front Mol Biosci，2023，10：1104505.
[18] Wang L，You LS，Ni WM，et al. Beta-Catenin and Akt Are Promising Targets for Combination Therapy in Acute Myeloid Leukemia [J]. Leuk Res，2013，37（10）：1329-1340.
[19] Zhang W，Lu Y，Zhen T，et al. Homoharringtonine Synergy With Oridonin in Treatment of T （8，21） Acute Myeloid Leu- kemia [J]. Front Med，2019，13（3）：38897.
[20] Shi X，Zhu M，Gong Z，et al. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways [J]. Food Chem Toxicol，2020，136：110960.
[21] Liu HY，Dong TX，Li ZZ，et al. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway [J]. Neoplasma，2021，68（5）：924-937.
[22] Sun Y，Dai J，Jiao R，et al. Homoharringtonine inhibits fibroblasts proliferation，extracellular matrix production and reduces surgery-induced knee arthrofibrosis via PI3K/AKT/ mTOR pathway-mediated apoptosis [J]. J Orthop Surg Res，2021，16（1）：9.
[23] 高小凤，张坤，张丽君，等.高三尖杉酯碱联合用药对急性髓系白血病细胞的增殖抑制[J].华西药学杂志，2021， 36（1）：35-38.
[24] 丁亦含，吴晶晶，王倩，等.高三尖杉酯碱通过mTOR通路诱导慢性髓系白血病K562细胞凋亡[J].中国实验血液学杂志，2018，26（1）：105-109.
[25] Guo L，Bai Y，Ji S，et al. MicroRNA-98 suppresses cell growth and invasion of retinoblastoma via targeting the IGF1R/ k-Ras/Raf/MEK/ERK signaling pathway[J]. Int J Oncol，2019，54（3）：807-820.
[26] Sakai H，Shiina I，Shinomiya T，et al. BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells，thereby inducing apoptosis and inhibiting cell growth [J]. Exp Ther Med，2021，21（5）：463.